This week, President Donald Trump is expected to outline new policies to deliver on his campaign pledge to bring down drug prices. The move will likely deal another blow to the U.S. pharmaceutical and healthcare sectors at a time when both are already under duress from rising competition, intensified scrutiny on pricing practices, and litigation related to negligent marketing of opioids and drug costs.
Americans spend over $450 billion on prescription medicines a year, three-quarters of which goes towards brand name drugs. But, alternatives in the form of generi...

 

To read more, sign up for a Free 30-Day Trial of MRP's research here.